• Users Online: 16
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 
Year : 2013  |  Volume : 5  |  Issue : 4  |  Page : 240-242

Metformin, the remarkable and unique antidiabetic agent

Whipps Cross University Hospital, Barts Health NHS Trust, London, United Kingdom

Correspondence Address:
Abdulfattah Ali Lakhdar
Whipps Cross University Hospital, Barts Health NHS Trust, London
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1947-489X.210551

Rights and Permissions

In the current issue of this Journal, Fiad and colleagues thoughtfully reviewed in detail the role of metformin in current clinical practice and highlighted the additional effects of metformin independent of the glycemic action of the drug. The review is comprehensive, up to date and is extensively supported by the literature. Metformin remains the first drug of choice in patients diagnosed with type 2 diabetes. Its vascular protection actions are particularly interesting though not yet fully understood. Its antineoplastic actions are very exciting. The authors clarify the issues of gastrointestinal side effects and renal limitations of its use and give practical ways of minimizing the potential loss of benefit to all treated patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded65    
    Comments [Add]    

Recommend this journal